Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential

3. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Upside Potential as of April 28: 56.39%

Viking Global’s Stake Value: $689,319,993

Number of Hedge Fund Holders: 48

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company that develops treatments for genetic diseases and cancers. Its products include therapies targeting rare conditions and innovative cancer treatments. The company operates mainly in the US, Japan, and Europe but has global end markets.

In Q4 2024, BridgeBio’s (NASDAQ:BBIO) revenue was $5.9 million, a substantial growth from $1.7 million in the same period in fiscal year 2023. Full-year revenue reached $221.9 million, many multiples more than the $9.3 million posted in 2023. According to the company, this growth was driven by the commercial launch of Attruby and licensing agreements. The company ended the fourth quarter with $681.2 million in cash and cash equivalents and expects to receive $105 million in regulatory milestones in the first half of 2025.

BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) flagship product, Attruby, saw 1,028 prescriptions by 516 prescribers by February; it earned EU approval (BEYONTTRA) with a $75M milestone and Japanese approval in March 2025, triggering a $30M milestone. On April 15, 2025, H.C. Wainwright analyst Raghuram Selvaraju raised BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) price target to $53 from $49, maintaining a Buy rating on the shares.